Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer

Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer

Abstract The combination of atezolizumab and nab-paclitaxel is recommended in the EU as first-line treatment for PD-L1-positive metastatic triple-negative breast cancer (mTNBC), based on the results of phase III IMpassion130 trial. However, ‘real-world’ data on this combination are limited. The ANAS...

Full description

Bibliographic Details
Main Authors: Alessandra Fabi, Luisa Carbognin, Andrea Botticelli, Ida Paris, Paola Fuso, Maria Cristina Savastano, Nicla La Verde, Carla Strina, Rebecca Pedersini, Stefania Guarino, Giuseppe Curigliano, Carmen Criscitiello, Mimma Raffaele, Alessandra Beano, Antonio Franco, Maria Rosaria Valerio, Francesco Verderame, Andrea Fontana, Eva Regina Haspinger, Alessia Caldara, Alba Di Leone, Giampaolo Tortora, Diana Giannarelli, Giovanni Scambia
Format: Article
Language:English
Published: Nature Portfolio 2023-09-01
Series:npj Breast Cancer
Online Access:https://doi.org/10.1038/s41523-023-00579-2

Internet

https://doi.org/10.1038/s41523-023-00579-2

Similar Items